Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duodart versus watchful waiting with step-up tamsulosin in treatment-naive men with moderately symptomatic BPH
NL-OMON38047Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of alpha blocker + 5-alpha reductase inhibitor, tamsulosin and dutasteride in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Started Nov 2010; status: active, not recruiting.
02
Drugs
alpha blocker + 5-alpha reductase inhibitortamsulosindutasteride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NL-OMON38047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38047.